Zylö Therapeutics Inc.

Zylö Therapeutics Inc. is a biotechnology firm specializing in innovative topical delivery systems through its proprietary Z-pods technology, aimed at enhancing therapeutic efficacy and patient adherence in pharmaceutical and cosmetic applications. Founded in 2017 and headquartered in Greenville, US, Zylö Therapeutics Inc. focuses on developing advanced delivery systems for therapeutic agents.

The company has raised funding across 6 deals, with its latest round being a Series B funding of USD 5. 23 million on June 3, 2022, supported by investors including Boston Harbor Angels and Harvard Business School Alumni Angels. The firm is led by CEO Scott Pancoast, who has a history of founding and managing companies in the biotech sector. Zylö Therapeutics specializes in enhancing topical delivery through its proprietary Z-pods technology, a unique encapsulation method designed for sustained delivery of therapeutic agents.

The core product offerings focus on pharmaceutical and cosmetic applications, targeting improved efficacy and patient compliance in topical treatments. By utilizing the Z-pods system, Zylö Therapeutics aims to address common challenges in drug delivery, such as variable absorption rates and inconsistent therapeutic outcomes. The company primarily serves a diverse client base, including pharmaceutical manufacturers, skincare brands, and healthcare providers, focusing on markets in North America and Europe. These products are strategically developed to cater to both consumer and clinical applications, ensuring they meet the specific needs of end-users seeking effective topical solutions.

Zylö Therapeutics generates revenue through partnerships and collaborations with pharmaceutical and cosmetic companies, leveraging its innovative Z-pods technology for their product offerings. The company engages in business transactions primarily through B2B agreements, where clients license the Z-pods technology or integrate it into their own formulations. This structure facilitates a consistent revenue stream as clients may pay upfront licensing fees or ongoing royalties based on product sales. The company’s flagship Z-pods technology is integral to their business model, allowing for scalable solutions tailored to the needs of various clients.

Specific pricing plans and detailed transaction structures are established on a case-by-case basis, ensuring that both Zylö Therapeutics and its partners achieve mutually beneficial agreements while maximizing the potential of their respective products in the marketplace. Following the recent Series B funding of USD 5. 23 million in June 2022, Zylö Therapeutics plans to enhance its internal research projects and accelerate the manufacturing process of its Z-pod® delivery particles. The funding will also be utilized to fully implement ISO-9001 and cGMP quality systems.

The company is focused on developing new product lines tailored for expanded market reach into both North America and Europe, with specific attention on consumer health and clinical applications. These initiatives are expected to drive growth and innovation within their product offerings.